Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 6/8/2023 | $6.50 → $6.20 | Underperform | Wedbush | |
| 2/7/2023 | Hold → Sell | Odeon | ||
| 2/6/2023 | $3.50 | Outperform | Noble Capital Markets | |
| 9/30/2022 | $7.50 | Sell → Hold | Odeon | |
| 9/1/2022 | Mkt Perform → Underperform | Raymond James | ||
| 8/18/2022 | $5.00 | Neutral → Underperform | Wedbush | |
| 8/16/2022 | $7.50 | Hold → Sell | Odeon | |
| 8/16/2022 | $5.00 | Neutral → Sell | B. Riley Securities |
GRAPEVINE, Texas, Sept. 10, 2024 (GLOBE NEWSWIRE) -- GameStop Corp. (NYSE:GME) ("GameStop" or the "Company") today released financial results for the second quarter ended August 3, 2024. The Company's condensed and consolidated financial statements, including GAAP and non-GAAP results, are below. The Company's Form 10-Q and supplemental information can be found at https://investor.gamestop.com. SECOND QUARTER OVERVIEW Net sales were $0.798 billion for the second quarter, compared to $1.164 billion in the prior year's second quarter.Selling, general and administrative ("SG&A") expenses were $270.8 million, or 33.9% of net sales for the second quarter, compared to $322.5 million, or 27
GRAPEVINE, Texas, June 07, 2024 (GLOBE NEWSWIRE) -- GameStop Corp. (NYSE:GME) ("GameStop" or the "Company") today released financial results for the first quarter ended May 4, 2024. The Company's condensed and consolidated financial statements, including GAAP and non-GAAP results, are below. FIRST QUARTER OVERVIEW Net sales were $0.882 billion for the first quarter, compared to $1.237 billion in the prior year's first quarter.Selling, general and administrative ("SG&A") expenses were $295.1 million, or 33.5% of net sales for the first quarter, compared to $345.7 million, or 27.9% of net sales, in the prior year's first quarter.Net loss was $32.3 million for the first quarter, compared to
GRAPEVINE, Texas, March 26, 2024 (GLOBE NEWSWIRE) -- GameStop Corp. (NYSE:GME) ("GameStop" or the "Company") today released financial results for the fourth quarter and fiscal year ended February 3, 2024. The Company's consolidated financial statements, including GAAP and non-GAAP results, are below. The Company's Form 10-K and supplemental information can be found at https://investor.gamestop.com. FOURTH QUARTER OVERVIEW Net sales were $1.794 billion for the fourth quarter, compared to $2.226 billion in the prior year's fourth quarter.Selling, general and administrative ("SG&A") expenses were $359.2 million, or 20.0% of net sales, for the fourth quarter, compared to $453.4 million, or 2
8-K - Jaguar Health, Inc. (0001585608) (Filer)
424B5 - Jaguar Health, Inc. (0001585608) (Filer)
8-K - Jaguar Health, Inc. (0001585608) (Filer)
Wedbush reiterated coverage of GameStop with a rating of Underperform and set a new price target of $6.20 from $6.50 previously
Odeon downgraded Bed Bath & Beyond from Hold to Sell
Noble Capital Markets initiated coverage of Newegg Commerce with a rating of Outperform and set a new price target of $3.50
4 - GameStop Corp. (0001326380) (Issuer)
4 - GameStop Corp. (0001326380) (Issuer)
4 - Jaguar Health, Inc. (0001585608) (Issuer)
Pitney Bowes Inc. (NYSE:PBI) ("Pitney Bowes" or the "Company"), a technology-driven company that provides SaaS shipping solutions, mailing innovation, and financial services to clients around the world, today announced the appointment of Lance Rosenzweig as the Company's permanent Chief Executive Officer ("CEO"), effective immediately. The Company's Board of Directors (the "Board") carried out an extensive CEO search process that was supported by a nationally recognized executive recruiting firm and included both internal and external candidates. After assessing Mr. Rosenzweig's considerable contributions as interim CEO and his track record of value creation at Pitney Bowes and at other co
FDA-approved Gelclair® is company's third commercialized prescription productSusan Krizancic appointed to role of National Sales Director at Jaguar family company Napo Pharmaceuticals SAN FRANCISCO, CA / ACCESSWIRE / September 10, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Susan Krizancic to the role of National Sales Director for Jaguar family company Napo Pharmaceuticals."Sue is a dynamic and proven commercial leader with 30 years of experience in the biopharmaceuticals industry - including 15 years of recent experience in the oncology market - building high-performing teams and exceeding sales targets. We ar
Benefits include free shipping, first access to new products and exclusive deals Newegg Commerce, Inc. (NASDAQ:NEGG), a leading global e-commerce company specializing in computers and consumer electronics, today announced the launch of Newegg+, a free customer membership program that offers substantial benefits. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423399970/en/Newegg+, a new free customer membership program from Newegg, offers a variety of desirable benefits. (Graphic: Newegg) Newegg+ elevates the Newegg shopping experience by giving members priority services like free shipping on millions of products, exclusive
SC 13G/A - Jaguar Health, Inc. (0001585608) (Subject)
SC 13D/A - GameStop Corp. (0001326380) (Subject)
SC 13G/A - Jaguar Health, Inc. (0001585608) (Subject)
Investors with a lot of money to spend have taken a bearish stance on GameStop (NYSE:GME). And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with GME, it often means somebody knows something is about to happen. So how do we know what these investors just did? Today, Benzinga's options scanner spotted 21 uncommon options trades for GameStop. This isn't normal. The overall sentiment of these big-money traders is split between 4% bullish and 90%, bearish. Out of all of the special optio
U.S. stocks traded slightly higher toward the end of trading, with the Dow Jones gaining by more than 50 points on Tuesday. The Dow traded up 0.17% to 40,483.92 while the NASDAQ rose 0.20% to 18,043.64. The S&P 500 also rose, gaining, 0.14% to 5,572.07. Check This Out: How To Earn $500 A Month From Alphabet Stock Ahead Of Q2 Earnings Report Leading and Lagging SectorsConsumer discretionary shares jumped by 0.5% on Tuesday. In trading on Tuesday, energy shares fell by 1.4%. Top Headline Coca-Cola Company (NYSE:KO) reported better-than-expected second-quarter results and raised its guidance. The company reported second-quarter FY24 sales growth of 3% year-on-year to $12.4
Shares of Comcast Corporation (NASDAQ:CMCSA) fell sharply during Tuesday's session after the company reported worse-than-expected second-quarter sales results. Comcast reported second-quarter revenue decline of 2.7% year-over-year to $29.69 billion, missing the analyst consensus estimate of $30.02 billion.The company reported adjusted EPS of $1.21, beating analyst consensus estimates of $1.12, according to data from Benzinga Pro. Comcast shares declined 6.1% to $37.12 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Azitra, Inc. (NYSE:AZTR) shares jumped 529% to $10.19 after the company announced that the U.S. Patent and Trademark Office grant
The combined net Q3 2024 revenue of approximately $3.1 million for prescription and non-prescription products, including license revenue, increased approximately 14% versus net Q2 2024 revenue of $2.7 million and 11% versus net Q3 2023 revenue of $2.8 millionJaguar reported significant results in breast cancer patients in its phase 3 OnTarget trial for its cancer supportive care drug crofelemer; results in breast cancer patients accepted for poster presentation on December 11, 2024 at the San Antonio Breast Cancer Symposium (SABCS)Jaguar initiated commercial launch in October 2024 for Gelclair®, the company's third prescription product, in alignment with Jaguar's focus on cancer supportive c
Click here to register for investor webcastCompany plans to file its Earnings Report on November 13, 2024 on Form 10-Q for the quarter ended September 30, 2024 SAN FRANCISCO, CA / ACCESSWIRE / November 11, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Wednesday, November 13, 2024 at 8:30 a.m. Eastern to review third-quarter 2024 financials and provide corporate updates.Participation Instructions for WebcastWhen: Wednesday, November 13, 2024 at 8:30 AM Eastern TimeParticipant Registration & Access Link: Click HereReplay Instructions for WebcastReplay of the webcast on the investor relations section of Jaguar's website: (click her
Canalevia®-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDABy prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree SAN FRANCISCO, CA / ACCESSWIRE / November 6, 2024 / Jaguar Health, Inc.(NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced that the U.S. Food and Drug Administration (FDA) has approved renewal of Canalevia-CA1 (crofelemer delayed-release tablets). Canalevia-CA1, the company's conditionally approved prescription drug for the treatment o
4 - GameStop Corp. (0001326380) (Issuer)
4 - GameStop Corp. (0001326380) (Issuer)
4 - Troika Media Group, Inc. (0001021096) (Issuer)